Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I studySarah P. Blagden, Essam Ghazaly, Ivana Rizzuto et al.|British Journal of Cancer|2018Cited by 43
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumorsRuth Plummer, Nagy Habib, Mikael H. Sodergren et al.|Cell Reports Medicine|2025Cited by 12
ProGem1: Phase I first-in-human study of the novel nucleotide NUC-1031 in adult patients with advanced solid tumors.Essam Ghazaly, Sarah P. Blagden, Simon Joel et al.|Journal of Clinical Oncology|2013Cited by 8
Final results of ProGem1, the first in-human phase I/II study of NUC-1031 in patients with solid malignancies.Sarah P. Blagden, Christopher McGuigan, Ivana Rizzuto et al.|Journal of Clinical Oncology|2015Cited by 7
A first in human Phase I/II study of NUC-1031 in patients with advanced gynecological cancers.Sarah P. Blagden, Essam Ghazaly, Ivana Rizzuto et al.|Journal of Clinical Oncology|2015Cited by 5